¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Subacute leukaemia of unspecified cell type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷, Á߽ɼ±¹æ¼¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷, ģũ·Ò¼¼Æ÷
  • chromophilic cell
    »ö¼Òµê¼¼Æ÷, È£»ö¼Ò¼¼Æ÷
  • chromophobic cell
    »ö¼Ò¾Èµê¼¼Æ÷
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • dust cell
    ¸ÕÁö¼¼Æ÷
  • delayed cell-mediated reaction
    Áö¿¬¼¼Æ÷¸Å°³¹ÝÀÀ
  • delta cell
    µ¨Å¸¼¼Æ÷
  • dendritic cell
    °¡Áö¼¼Æ÷, ¼öÁö»ó¼¼Æ÷
  • dark cell
    ¾îµÒ¼¼Æ÷
  • daughter cell
    µþ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¸Å°³¸é¿ª°áÇÌÁõÈıº
  • cell-mediated lympholysis test
    ¼¼Æ÷¸Å°³¸²ÇÁ±¸¿ëÇØ½ÃÇè
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • Chinese hamster ovary cell
    Áß±¹ºñ´ÜÅÐÁã³­¼Ò¼¼Æ÷
  • chromaffin cell
    ģũ·Ò¼¼Æ÷, Å©·Òģȭ¼¼Æ÷
  • chromophilic cell
    »ö¼Òµë¼¼Æ÷, È£»ö¼Ò¼¼Æ÷
  • chromophobic cell
    »ö¼Ò¾Èµë¼¼Æ÷
  • ciliated cell
    ¼¶¸ð¼¼Æ÷, ÀÜÅм¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • clear cell hidradenoma
    Åõ¸í¼¼Æ÷¶¡»ùÁ¾
  • clear cell sarcoma
    Åõ¸í¼¼Æ÷À°Á¾
  • columnar cell
    ¿øÁÖ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • Ts cell
    ¾ïÁ¦T¼¼Æ÷
  • Tzanck cell
    Á¤Å© ¼¼Æ÷
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • accessory cell
    º¸Á¶¼¼Æ÷, ºÎ¼ö¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    ¼±Æ÷ ¼¼Æ÷(àÍøàá¬øà)
  • acinar cell
    ¼±¹æ¼¼Æ÷(¡­á¬øà)
  • acinic cell carcinoma
    ¼±¹æ¼¼Æ÷¾ÏÁ¾(¡­á¬øàäßðþ)
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç(ÛöÕË ðþåÆ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • adult T Cell leukemia virus
    ¼ºÀÎ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • lepromatous type
    ³ªÁ¾Çü(ÑÛðþúþ)
  • lepromatous type
    ³ªÁ¾Çü(ÑÛðþúþ).
  • leptosomatic type
    ¸¶¸¥Çü(¡­úþ).
  • limb girdle type
    Áö´ëÇü.
  • linear array type
    ¼±Çü ¹è¿­½Ä (àÊû¡ ÛÕÖªãÒ)
  • linear type constitution
    ¼±Ã¼Çü.
  • lymphatic type
    ¸²ÇÁÇü(¡­úþ).
  • mating type
    ±³¹èÇü
  • men type
    MEN Çü(¡­ û¡)
  • meningeal type
    ¼ö¸·Çü(âÐØ¯úþ).
  • metaphyseal dysostosis dominant type
    °ñ °£´Ü¼º À̰ñÁõ ¿ì¼ºÇü(ÍéÊÏÓ®àõì¶ÍéñøéÐàõúþ).
  • metaplastic bone (type)
    È­»ý°ñ(Çü)(ûùßæÍéû¡).
  • mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü(¡­û¡).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • Central glial cell
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] Á߽ɽŰ汳¼¼Æ÷
  • Glial cell of central nervous system
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁßÃß±³¼¼Æ÷
  • Mesothelial cell
    ÁßÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÁßÇǼ¼Æ÷
  • Cuticular cell
    Áý²®Áú¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÇǼ¼Æ÷
  • Fenestrated endothelial cell
    â³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] À¯Ã¢³»ÇǼ¼Æ÷
  • Interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷
    [¿¾ ¿ë¾î] ûġ°£¼¼Æ÷
  • Merkel`s cell
    Ã˰¢¼¼Æ÷
    [¿¾ ¿ë¾î] MerkelÃ˰¢¼¼Æ÷
  • Macula densa cell
    Ä¡¹Ð¹ÝÁ¡¼¼Æ÷
    [¿¾ ¿ë¾î] Ä¡¹Ð¹Ý¼¼Æ÷
  • Chromaffin cell
    ģũ·Ò¼¼Æ÷
    [¿¾ ¿ë¾î] Å©·Òģȭ¼¼Æ÷
  • Golgi cell
    Å«º°¼¼Æ÷
    [¿¾ ¿ë¾î] °ñÁö¼¼Æ÷
  • Large cell part
    Å«¼¼Æ÷ºÎºÐ
    [¿¾ ¿ë¾î] ´ë¼¼Æ÷ºÎ
  • Decidual cell
    Å»¶ô¸·¼¼Æ÷
    [¿¾ ¿ë¾î] Å»¶ô¸·¼¼Æ÷
  • Cuticular cell
    Åв®Áú¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ð¼ÒÇǼ¼Æ÷
  • Matrix cell
    ÅйÙÅÁÁú¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ð±âÁú¼¼Æ÷
  • Hair cell
    Åм¼Æ÷
    [¿¾ ¿ë¾î] À¯¸ð°¨°¢¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
SCC self-care center; sequential combination chemotherapy; services for crippled children; short-course ...
SCM Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt...
TCE T-cell enriched; tetrachlorodiphenyl ethane; trichloroethylene T-cell thymus-derived cell
TCR T-cell reactivity; T-cell receptor; T-cell rosette; thalamocortical relay; total cytoplasmic ribosom...
WBC well baby care/clinic; white blood cell; white blood cell count; whole blood cell count
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
hLIF Human leukaemia inhibitory factor
HL-60 Human promyelocytic leukaemia
HL-60 Human promyelocytic leukaemia cells
JCML Juvenile chronic myelogenous leukaemia
JCML Juvenile chronic myeloid leukaemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell enclosure
    ¼¼Æ÷ ºÀÀÔü
    ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ¼¼Æ÷³»¿¡ ±èÀÚ ¾× µî¿¡ ÀÇÇØ ¿°»öµÈ °ú¸³»ó ¶Ç´Â ±× ¹ÛÀÇ Æ¯Â¡ÀÌ ÀÖ´Â ÇüŸ¦ º¸ÀÌ´Â ¼Òü. °£´ÜÈ÷ ºÀÀÔü¶ó°íµµ ÇÑ´Ù. ±¤°ßº´ µî ¹ÙÀÌ·¯½º º´À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÇ´Â ¼¼Æ÷ ºÀÀÔüÀÇ º»·¡ ÇüÅ¿¡ °üÇÑ ³íÀǰ¡ ¸¹¾ÒÀ¸³ª, Áö±ÝÀº ¹ÙÀÌ·¯½º º´ÀÇ º´¿øÃ¼ÀÓÀÌ È®ÀεǾú´Ù. ¼¼Æ÷ ºÀÀÔü¿¡´Â ¼¼Æ÷Áú³» ºÀÀÔü¿Í ¼¼Æ÷ÇÙ³» ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷Áú³» ºÀÀÔü¿¡´Â õ¿¬µÎ, ¿ìµÎÀÇ °¡¸£´Ï¿¡¸® ¼Òü, ±¤°ßº´ÀÇ ³×±×¸® ¼Òü µîÀÌ ÀÖ´Ù. À̵éÀº È£»ê¼º, ¿øÇü, ±ÕÁú ¶Ç´Â °ú¸³»ó ±¸Á¶¸¦ °¡Áø °Í°ú Æ®¶óÄÚ¸¶ÀÇ ÇÁ·Î¹Ùüũ ¼Òü µî È£¿°±â¼ºÀ¸·Î º¹ÀâÇÑ ÇüÀ» °¡Áø °ÍÀÌ ÀÖ´Ù. ¼¼Æ÷ÇÙ³» ºÀÀÔü¿¡´Â Ç츣Æä½º À¯¹ß ¹ÙÀÌ·¯½º·Î Çü¼ºµÈ ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷ ºÀÀÔü¸¦ ÇÔÀ¯ ³»¿ë¹°¿¡ µû¶ó ºÐ·ùÇϸé, ¹ÙÀÌ·¯½º°¡ ¸ðÀÎ °Í°ú ¹ÙÀÌ·¯½º ±¸¼º ¹°Áú·Î µÈ °ÍÀÌ ¸ðÀÎ °Í, ±×¸®°í ¹ÙÀÌ·¯½ºÀÇ ¼ººÐ°ú °ü·ÃÀÌ ¾ø´Â ƯÀ¯ÇÑ ´Ü¹éÁú·Î ÀÌ·ç¾îÁø °Í µî 3Á¾·ù·Î ³ª´¶´Ù. ¼¼Æ÷ ºÀÀÔüÀÇ Çü¼ºÀº ÁÖ·Î ¹ÙÀÌ·¯½ºÀÇ °¨¿°°ú °ü·ÃµÇ³ª À̿ܿ¡µµ Áß±Ý¼Ó µîÀÇ ¾àǰ Åõ¿©³ª ¼¼Æ÷´ë»ç Àå¾Ö¸¦ ÀÏÀ¸Å°´Â °Í¿¡ ÀÇÇÏ¿© ³ªÅ¸³ª±âµµ ÇÑ´Ù. ¿¹¸¦ µé¸é, ÁßÃ߽Űæ°èÀÇ ÁúȯÀÎ ÆÄŲ½¼ º´ÀÇ °æ¿ì ½Å°æ¼¼Æ÷³»¿¡¼­ ·¹ºß ¼Òü¶ó´Â ¼Òü¸¦, ¹Ì¿ÀŬ·Î´©½º °£Áú ȯÀÚÀÇ ³ú³ª ô¼öÀÇ ½Å°æ¼¼Æ÷³»¿¡¼­´Â ¹Ì¿ÀŬ·Î´©½º ¼Òü¸¦ º¼ ¼ö Àִµ¥ À̵éÀº ¸ðµÎ ¼¼Æ÷Áú³» ºÀÀÔüÀÌ´Ù.
  • cell fusion
    ¼¼Æ÷ ÀÀÇÕ, ¼¼Æ÷ À¶ÇÕ
    µÎ Á¾·ù ÀÌ»óÀÇ ¼¼Æ÷¸¦ ¹ÙÀÌ·¯½º,
  • cell harverter
    ¼¼Æ÷ ȸ¼ö±â
    ´Ù¼öÀÇ ¼¼Æ÷ ¹è¾ç ¿ë±â¿¡¼­ µ¿½Ã¿¡ ¹è¾çµÈ ´É·üÀÌ ÁÁÀº ¼¼Æ÷¸¦ äÃëÇÏ´Â ±â±âÀÇ ÃÑĪ.
  • cell hybridization
    ¼¼Æ÷ ÇÏÀ̺긮µå Çü¼º
  • cell injury
    ¼¼Æ÷ ¼Õ»ó
  • cell interface
    ¼¼Æ÷ »çÀÌ ¸é, ¼¼Æ÷ °£¸é
  • cell kinetics
    ¼¼Æ÷ ¿ªÇÐ
  • cell lethality
    ¼¼Æ÷ Ä¡»çÀ²
  • cell line
    ¼¼Æ÷°è
  • cell mass
    ¿ø±â ¼¼Æ÷±º
  • cell mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª ÀÛ¿ë, ¼¼Æ÷¼º ¸é¿ª
    Ç׿øÀÌ T Àӯı¸¸¦ ÀÚ±ØÇÏ¸é ¸é¿ª ±Û·ÎºÒ¸°À» ÇÕ¼º ºÐºñÇÏ´Â °ÍÀÌ ¾Æ´Ï°í Àӯı¸ ÀÚ½ÅÀÌ Ç×ü·Î ÀÛ¿ëÇÏ´Â °¨ÀÛ Àӯı¸°¡ µÇ´Â °ÍÀÌ Ã¼¾×¼º ¸é¿ª°úÀÇ Â÷ÀÌ·Î, ü¾×¼º ¸é¿ªÀÌ ÁÖ·Î ±Þ¼º ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀε¥ ºñÇØ¼­ ¼¼Æ÷¼º ¸é¿ªÀº ¸¸¼º ¼¼±Õ¼º Áúȯ, Á¶Á÷ À̽Ä, ¾Ï ¼¼Æ÷, °õÆÎÀÌ Áúȯ, ƯÈ÷ ¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀÌ´Ù.
  • cell mediated lympholysis
    ¼¼Æ÷ ¸Å°³ ¸²ÇÁ±¸ ¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷ ¸Å°³¼º ¹ÝÀÀ
  • cell membrane permeability
    ¼¼Æ÷¸· Åõ°ú¼º
  • cell of parathyroid gland
    ºÎ°©»ó»ù ¼¼Æ÷, ºÎ°©»ó¼± ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
viral hepatitis type E Hepatitis caused by a nonenveloped, single-stranded, positive-sense RNA virus 27-34 nm in diameter, unrelated to other hepatitis; it is the principal cause of enterically transmitted, waterborne, epidemic NANB hepatitis occurring primarily in Asia and Africa.
Synonym: hepatitis E.
(05 Mar 2000)
central Recklinghausen's disease type II type 1 neurofibromatosis
central type neurofibromatosis Type I neurofibromatosis.
Incomplete neurofibromatosis, multiple neurofibromas with minimal manifestations, perhaps limited to cafe-au-lait spots; individuals with minimal lesions may have offspring with severe involvement.
Synonym: abortive neurofibromatosis.
(05 Mar 2000)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
V-type ATPase <enzyme> From eukaryotic endomembrane systems, including vacuoles, lysosomes, golgi apparatus, chromaffin granules and coated vesicles. One of three major classes of ion transport ATPase, characterised by a multi subunit structure and a lack of a phosphorylated intermediate.
Found in archaebacteria but not eubacteria, in the intracellular acidic vacuoles and in some proton pumping epithelia (e.g. Intercalated cells of kidney). A complex enzyme encoded by several genes, involved in ion translocation but does not act via phosphorylated enzyme intermediate
See: P-type ATPase.
Registry number: EC 3.6.1.-
Synonym: atpase, v-type, atpase, vacuolar, vacuolar atpase, v-atpase, vacuolar h+-atpase, vacuolar membrane h(+)-atpase, vha55 gene product, vma16 gene product
(26 Jun 1999)
Gm type <immunology> Genetically determined allotypic antigens found on IgG of some individuals.
(18 Nov 1997)
Golgi type II neuron <physiology> Nerve cells with short axons which ramify in the gray matter.
(05 Mar 2000)
Golgi type I neuron <physiology> Nerve cells whose long axons leave the gray matter of which they form a part.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á